{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:37:33Z","timestamp":1779190653824,"version":"3.51.4"},"reference-count":137,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002543","name":"Pusan National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002515","name":"Korea National Open University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002515","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Liver Research"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.livres.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T03:49:20Z","timestamp":1656647360000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"7","author":[{"given":"Ye Eun","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong Seong","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-3603","authenticated-orcid":false,"given":"Seonghwan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.livres.2022.06.001_bib1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.livres.2022.06.001_bib2","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.28368","article-title":"Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study","volume":"63","author":"Piscaglia","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib3","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.livres.2022.06.001_bib4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis of nonalcoholic steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.livres.2022.06.001_bib5","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2016.01.025","article-title":"Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?","volume":"150","author":"Gao","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2022.06.001_bib6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","article-title":"Non-alcoholic fatty liver disease: an expanded review","volume":"9","author":"Benedict","year":"2017","journal-title":"World J Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib7","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/10409231003667500","article-title":"Genetic control of de novo lipogenesis: role in diet-induced obesity","volume":"45","author":"Strable","year":"2010","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"10.1016\/j.livres.2022.06.001_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.livres.2022.06.001_bib9","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20060499","article-title":"Insulin activates human sterol-regulatory-element-binding protein-1c (SREBP-1c) promoter through SRE motifs","volume":"400","author":"Dif","year":"2006","journal-title":"Biochem J"},{"key":"10.1016\/j.livres.2022.06.001_bib10","first-page":"19","article-title":"Insulin and insulin resistance","volume":"26","author":"Wilcox","year":"2005","journal-title":"Clin Biochem Rev"},{"key":"10.1016\/j.livres.2022.06.001_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cmet.2007.12.009","article-title":"Selective versus total insulin resistance: a pathogenic paradox","volume":"7","author":"Brown","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2022.06.001_bib12","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.cmet.2007.11.013","article-title":"Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis","volume":"7","author":"Biddinger","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2022.06.001_bib13","doi-asserted-by":"crossref","first-page":"19353","DOI":"10.1074\/jbc.M201584200","article-title":"Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)\/Lep(ob) mice","volume":"277","author":"Yahagi","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.livres.2022.06.001_bib14","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.3390\/nu7064995","article-title":"Hepatic steatosis as a marker of metabolic dysfunction","volume":"7","author":"Fabbrini","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.livres.2022.06.001_bib15","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1172\/JCI117271","article-title":"Multiple lipolysis defects in the insulin resistance (metabolic) syndrome","volume":"93","author":"Reynisdottir","year":"1994","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.livres.2022.06.001_bib16","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.livres.2022.06.001_bib17","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J\u00a0Gastroenterol"},{"key":"10.1016\/j.livres.2022.06.001_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.22363","article-title":"Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis","volume":"48","author":"Wouters","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.livres.2022.06.001_bib20","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/hep.30333","article-title":"Mouse models of nonalcoholic steatohepatitis: toward optimization of their relevance to human nonalcoholic steatohepatitis","volume":"69","author":"Farrell","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib21","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1194\/jlr.M034876","article-title":"Hepatic cholesterol crystals and crown-like structures distinguish NASH from simple steatosis","volume":"54","author":"Ioannou","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.livres.2022.06.001_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082163","article-title":"Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans","volume":"8","author":"Itoh","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2022.06.001_bib23","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1007\/s11695-007-9219-7","article-title":"Effect of high fat diet on the volume of liver and quantitative feature of Kupffer cells in the female rat: a stereological and ultrastructural study","volume":"17","author":"Kiki","year":"2007","journal-title":"Obes Surg"},{"key":"10.1016\/j.livres.2022.06.001_bib24","doi-asserted-by":"crossref","first-page":"G1310","DOI":"10.1152\/ajpgi.00365.2011","article-title":"Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2","volume":"302","author":"Miura","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.livres.2022.06.001_bib25","doi-asserted-by":"crossref","first-page":"40161","DOI":"10.1074\/jbc.M112.417014","article-title":"Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-\u03b1 production","volume":"287","author":"Tosello-Trampont","year":"2012","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.livres.2022.06.001_bib26","doi-asserted-by":"crossref","first-page":"17192","DOI":"10.1038\/srep17192","article-title":"Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: a comparison with vitamin E","volume":"5","author":"Ni","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.livres.2022.06.001_bib27","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/path.5275","article-title":"Bone marrow-derived macrophage contributes to fibrosing steatohepatitis through activating hepatic stellate cells","volume":"248","author":"Han","year":"2019","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.livres.2022.06.001_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41423-020-00579-3","article-title":"Immunological mechanisms and therapeutic targets of fatty liver diseases","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.livres.2022.06.001_bib29","first-page":"31","article-title":"The role of innate immune cells in nonalcoholic fatty liver disease","volume":"14","author":"Nati","year":"2022","journal-title":"J\u00a0Innate Immun"},{"key":"10.1016\/j.livres.2022.06.001_bib30","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8162421","article-title":"The role of tissue macrophage-mediated inflammation on NAFLD pathogenesis and its clinical implications","volume":"2017","author":"Alisi","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.livres.2022.06.001_bib31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.24341","article-title":"Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells","volume":"54","author":"Csak","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib32","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3389\/fimmu.2017.01728","article-title":"Relevance of the NLRP3 inflammasome in the pathogenesis of chronic liver disease","volume":"8","author":"Wu","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.livres.2022.06.001_bib33","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J\u00a0Mol Med (Berl)"},{"key":"10.1016\/j.livres.2022.06.001_bib35","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2012.03.035","article-title":"Inflammasomes in liver diseases","volume":"57","author":"Szabo","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6489012","article-title":"Role of NLRP3 inflammasome in the progression of NAFLD to NASH","author":"Wan","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib37","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nrgastro.2017.35","article-title":"NAFLD: a critical role for the NLRP3 inflammasome in NASH","volume":"14","author":"Thomas","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib38","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s10753-017-0628-z","article-title":"NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in Kupffer cells induced by palmitic acid","volume":"40","author":"Cai","year":"2017","journal-title":"Inflammation"},{"key":"10.1016\/j.livres.2022.06.001_bib39","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.livres.2022.06.001_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1172\/JCI38388","article-title":"Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice","volume":"120","author":"Wueest","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.livres.2022.06.001_bib41","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1074\/jbc.M109.074252","article-title":"Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis","volume":"285","author":"Alkhouri","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.livres.2022.06.001_bib42","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/hep.30525","article-title":"Adipocyte death preferentially induces liver injury and inflammation through the activation of chemokine (C-C motif) receptor 2-positive macrophages and lipolysis","volume":"69","author":"Kim","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib43","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1136\/gutjnl-2016-313654","article-title":"Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice","volume":"67","author":"Bijnen","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.livres.2022.06.001_bib44","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nri.2016.70","article-title":"A\u00a0guide to immunometabolism for immunologists","volume":"16","author":"O\u2019Neill","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.livres.2022.06.001_bib45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-0037-1604480","article-title":"Macrophages in nonalcoholic fatty liver disease: a role model of pathogenic immunometabolism","volume":"37","author":"Krenkel","year":"2017","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.livres.2022.06.001_bib46","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/hep.27985","article-title":"Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells","volume":"62","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib47","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100299","article-title":"Triggering MSR1 promotes JNK-mediated inflammation in IL-4-activated macrophages","volume":"38","author":"Guo","year":"2019","journal-title":"EMBO J"},{"key":"10.1016\/j.livres.2022.06.001_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1161\/ATVBAHA.108.176644","article-title":"Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice","volume":"29","author":"Manning-Tobin","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.livres.2022.06.001_bib49","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jhep.2021.12.012","article-title":"Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease","volume":"76","author":"Govaere","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib50","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nature13989","article-title":"Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors","volume":"518","author":"Gomez Perdiguero","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.livres.2022.06.001_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/cells7080103","article-title":"Understanding the biology of self-renewing macrophages","volume":"7","author":"R\u00f6szer","year":"2018","journal-title":"Cells"},{"key":"10.1016\/j.livres.2022.06.001_bib52","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib53","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1126\/science.1251414","article-title":"The transcription factor Gata6 links tissue macrophage phenotype and proliferative renewal","volume":"344","author":"Rosas","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.livres.2022.06.001_bib54","doi-asserted-by":"crossref","first-page":"7294","DOI":"10.1038\/s41467-021-27614-9","article-title":"Directly recruited GATA6 + peritoneal cavity macrophages contribute to the repair of intestinal serosal injury","volume":"12","author":"Honda","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.livres.2022.06.001_bib55","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.immuni.2017.07.018","article-title":"A\u00a0liver capsular network of monocyte-derived macrophages restricts hepatic dissemination of intraperitoneal bacteria by neutrophil recruitment","volume":"47","author":"Sierro","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.livres.2022.06.001_bib56","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3389\/fimmu.2019.01084","article-title":"Macrophage polarization: different gene signatures in M1(LPS+) vs. classically and M2(LPS-) vs. alternatively activated macrophages","volume":"10","author":"Orecchioni","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.livres.2022.06.001_bib57","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22034","article-title":"Liver: an organ with predominant innate immunity","volume":"47","author":"Gao","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib58","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3389\/fimmu.2019.02694","article-title":"Understanding the heterogeneity of resident liver macrophages","volume":"10","author":"Bl\u00e9riot","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.livres.2022.06.001_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells8091032","article-title":"Phenotypical and functional polymorphism of liver resident macrophages","volume":"8","author":"Elchaninov","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.livres.2022.06.001_bib60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jhepr.2019.02.004","article-title":"Macrophages in obesity and non-alcoholic fatty liver disease: crosstalk with metabolism","volume":"1","author":"Lefere","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.livres.2022.06.001_bib61","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1126\/science.1175202","article-title":"Identification of splenic reservoir monocytes and their deployment to inflammatory sites","volume":"325","author":"Swirski","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.livres.2022.06.001_bib62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1172\/JCI200522675","article-title":"Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair","volume":"115","author":"Duffield","year":"2005","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.livres.2022.06.001_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.livres.2022.06.001_bib64","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/gutjnl-2019-318382","article-title":"Myeloid cells in liver and bone marrow acquire a functionally distinct inflammatory phenotype during obesity-related steatohepatitis","volume":"69","author":"Krenkel","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.livres.2022.06.001_bib65","doi-asserted-by":"crossref","first-page":"7249","DOI":"10.3390\/ijms22147249","article-title":"Liver injury and the macrophage issue: molecular and mechanistic facts and their clinical relevance","volume":"22","author":"Roohani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.livres.2022.06.001_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159524","article-title":"Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation","volume":"11","author":"Reid","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2022.06.001_bib67","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1111\/liv.14696","article-title":"Intestinal permeability in human nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"40","author":"De Munck","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.livres.2022.06.001_bib68","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3748\/wjg.v23.i4.712","article-title":"Association between endotoxemia and histological features of nonalcoholic fatty liver disease","volume":"23","author":"Kitabatake","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.livres.2022.06.001_bib69","first-page":"344","article-title":"Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology","volume":"3","author":"Weiskirchen","year":"2014","journal-title":"Hepatobiliary Surg Nutr"},{"key":"10.1016\/j.livres.2022.06.001_bib70","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep4.1158","article-title":"Tumor necrosis factor-\u03b1-mediated hepatocyte apoptosis stimulates fibrosis in the steatotic liver in mice","volume":"2","author":"Osawa","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.livres.2022.06.001_bib71","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1186\/1755-1536-5-S1-S27","article-title":"Functional role of intrahepatic monocyte subsets for the progression of liver inflammation and liver fibrosis in\u00a0vivo","volume":"5","author":"Tacke","year":"2012","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1016\/j.livres.2022.06.001_bib72","first-page":"3835","article-title":"Role of macrophages in experimental liver injury and repair in mice","volume":"17","author":"Dong","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.livres.2022.06.001_bib73","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3390\/biomedicines9081014","article-title":"Extra- and intra-cellular mechanisms of hepatic stellate cell activation","volume":"9","author":"Yan","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.livres.2022.06.001_bib74","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.immuni.2020.06.003","article-title":"Impaired Kupffer cell self-renewal alters the liver response to lipid overload during non-alcoholic steatohepatitis","volume":"53","author":"Tran","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.livres.2022.06.001_bib75","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.immuni.2020.08.004","article-title":"Osteopontin expression identifies a subset of recruited macrophages distinct from Kupffer cells in the fatty liver","volume":"53","author":"Remmerie","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.livres.2022.06.001_bib76","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.cell.2019.05.054","article-title":"Lipid-associated macrophages control metabolic homeostasis in a trem2-dependent manner","volume":"178","author":"Jaitin","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.livres.2022.06.001_bib77","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-018-0298-9","article-title":"New insights into the role of TREM2 in Alzheimer\u2019s disease","volume":"13","author":"Gratuze","year":"2018","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.livres.2022.06.001_bib78","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3389\/fncel.2018.00206","article-title":"Microglial TREM2\/DAP12 signaling: a double-edged sword in neural diseases","volume":"12","author":"Konishi","year":"2018","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.livres.2022.06.001_bib79","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Mol Cell"},{"key":"10.1016\/j.livres.2022.06.001_bib80","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.immuni.2020.04.001","article-title":"Niche-specific reprogramming of epigenetic landscapes drives myeloid cell diversity in nonalcoholic steatohepatitis","volume":"52","author":"Seidman","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.livres.2022.06.001_bib81","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.livres.2022.06.001_bib82","doi-asserted-by":"crossref","DOI":"10.1172\/JCI135197","article-title":"TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis","volume":"131","author":"Hou","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.livres.2022.06.001_bib83","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818815184","article-title":"Function and therapeutic advances of chemokine and its receptor in nonalcoholic fatty liver disease","volume":"11","author":"Chen","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.livres.2022.06.001_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic effects of the dual CCR2\/CCR5 antagonist cenicriviroc in animal models of liver and kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2022.06.001_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184694","article-title":"Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury","volume":"12","author":"Puengel","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2022.06.001_bib86","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1136\/gutjnl-2011-300304","article-title":"Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury","volume":"61","author":"Baeck","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.livres.2022.06.001_bib87","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/hep.29544","article-title":"Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis","volume":"67","author":"Krenkel","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib88","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/hep4.1160","article-title":"Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis","volume":"2","author":"Kruger","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.livres.2022.06.001_bib89","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A\u00a0randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib90","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/jac\/dku071","article-title":"Maraviroc, a CCR5 antagonist, ameliorates the development of hepatic steatosis in a mouse model of non-alcoholic fatty liver disease (NAFLD)","volume":"69","author":"P\u00e9rez-Mart\u00ednez","year":"2014","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.livres.2022.06.001_bib91","doi-asserted-by":"crossref","first-page":"26125","DOI":"10.1074\/jbc.M115.651489","article-title":"Binding of galectin-3, a \u03b2-galactoside-binding lectin, to MUC1 protein enhances phosphorylation of extracellular signal-regulated kinase 1\/2 (ERK1\/2) and akt, promoting tumor cell malignancy","volume":"290","author":"Mori","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.livres.2022.06.001_bib92","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1002\/JLB.3VMR0118-036R","article-title":"Galectin-3-binding protein: a multitask glycoprotein with innate immunity functions in viral and bacterial infections","volume":"104","author":"Loimaranta","year":"2018","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.livres.2022.06.001_bib93","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/9247574","article-title":"The many roles of galectin-3, a multifaceted molecule, in innate immune responses against pathogens","volume":"2017","author":"D\u00edaz-Alvarez","year":"2017","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.livres.2022.06.001_bib94","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1073\/pnas.0511167103","article-title":"Galectin-3 regulates myofibroblast activation and hepatic fibrosis","volume":"103","author":"Henderson","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.livres.2022.06.001_bib95","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.114.218370","article-title":"Functions of galectin-3 and its role in fibrotic diseases","volume":"351","author":"Li","year":"2014","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.livres.2022.06.001_bib96","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/17512433.2021.1894127","article-title":"Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis","volume":"14","author":"Al Attar","year":"2021","journal-title":"Expet Rev Clin Pharmacol"},{"key":"10.1016\/j.livres.2022.06.001_bib97","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083481","article-title":"Therapy of experimental NASH and fibrosis with galectin inhibitors","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.livres.2022.06.001_bib98","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1053\/j.gastro.2019.11.296","article-title":"Effects of eelapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension","volume":"158","author":"Chalasani","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2022.06.001_bib99","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jhep.2010.09.020","article-title":"Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver","volume":"54","author":"Iacobini","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib100","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/apt.13816","article-title":"Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis","volume":"44","author":"Harrison","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.livres.2022.06.001_bib101","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/cr.2008.289","article-title":"FXR: a metabolic regulator and cell protector","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.livres.2022.06.001_bib102","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.bbrc.2015.10.056","article-title":"Activation of farnesoid X receptor downregulates monocyte chemoattractant protein-1 in murine macrophage","volume":"467","author":"Li","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.livres.2022.06.001_bib103","doi-asserted-by":"crossref","first-page":"14430","DOI":"10.3748\/wjg.v20.i39.14430","article-title":"FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation","volume":"20","author":"Yao","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.livres.2022.06.001_bib104","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1074\/jbc.M112.446575","article-title":"Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease","volume":"288","author":"McMahan","year":"2013","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.livres.2022.06.001_bib105","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jhep.2009.03.025","article-title":"Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis","volume":"51","author":"Zhang","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib106","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.livres.2022.06.001_bib107","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2022.06.001_bib108","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.livres.2022.06.001_bib109","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.2147\/DDDT.S315724","article-title":"Non-alcoholic steatohepatitis (NASH) - a review of a crowded clinical landscape, driven by a complex disease","volume":"15","author":"Fraile","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.livres.2022.06.001_bib110","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.31205","article-title":"Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial","volume":"72","author":"Patel","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.livres.2022.06.001_bib111","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1021\/acs.jmedchem.9b01621","article-title":"Nidufexor (LMB763), a novel FXR modulator for the treatment of nonalcoholic steatohepatitis","volume":"63","author":"Chianelli","year":"2020","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.livres.2022.06.001_bib112","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/17460441.2021.1916465","article-title":"The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease","volume":"16","author":"Fiorucci","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.livres.2022.06.001_bib113","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2021.01.047","article-title":"A\u00a0structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis","volume":"75","author":"Harrison","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.livres.2022.06.001_bib114","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4103\/2231-4040.90879","article-title":"The peroxisome proliferator-activated receptor: a family of nuclear receptors role in various diseases","volume":"2","author":"Tyagi","year":"2011","journal-title":"J\u00a0Adv Pharm Technol Res"},{"key":"10.1016\/j.livres.2022.06.001_bib115","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.3390\/ijms21062061","article-title":"PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice","volume":"21","author":"Wang","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.livres.2022.06.001_bib116","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1210\/me.2003-0151","article-title":"The peroxisome proliferator-activated receptor beta\/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells","volume":"17","author":"Dressel","year":"2003","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.livres.2022.06.001_bib117","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbadis.2004.11.011","article-title":"Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes","volume":"1740","author":"Luquet","year":"2005","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.livres.2022.06.001_bib118","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.febslet.2010.06.010","article-title":"PPARgamma in adipocyte differentiation and metabolism--novel insights from genome-wide studies","volume":"584","author":"Siersbaek","year":"2010","journal-title":"FEBS Lett"},{"key":"10.1016\/j.livres.2022.06.001_bib119","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2020.00730","article-title":"Peroxisome proliferator-activated receptors: experimental targeting for the treatment of inflammatory bowel diseases","volume":"11","author":"Decara","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.livres.2022.06.001_bib120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.bbalip.2007.02.013","article-title":"PPARs and molecular mechanisms of transrepression","volume":"1771","author":"Ricote","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.livres.2022.06.001_bib121","doi-asserted-by":"crossref","first-page":"8330","DOI":"10.18632\/oncotarget.2212","article-title":"Peroxisome proliferator activated receptor alpha inhibits hepatocarcinogenesis through mediating NF-\u03baB signaling pathway","volume":"5","author":"Zhang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.livres.2022.06.001_bib122","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.livres.2022.06.001_bib123","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.3390\/ijms19113339","article-title":"The role of PPAR-\u03b4 in metabolism, inflammation, and cancer: many characters of a critical transcription factor","volume":"19","author":"Liu","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.livres.2022.06.001_bib124","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/nm.2048","article-title":"PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance","volume":"15","author":"Mukundan","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.livres.2022.06.001_bib125","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1093\/nar\/gkv331","article-title":"The transcriptional PPAR\u03b2\/\u03b4 network in human macrophages defines a unique agonist-induced activation state","volume":"43","author":"Adhikary","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.livres.2022.06.001_bib126","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/phar.2489","article-title":"Emerging therapies for the treatment of nonalcoholic steatohepatitis: a systematic review","volume":"41","author":"Guirguis","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.livres.2022.06.001_bib127","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.livres.2022.06.001_bib128","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40261-013-0128-3","article-title":"Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPAR\u03b1 agonist with moderate PPAR\u03b3 agonist activity in healthy human subjects","volume":"33","author":"Jani","year":"2013","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.livres.2022.06.001_bib129","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1038\/s41598-020-66458-z","article-title":"The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease","volume":"10","author":"Kumar","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.livres.2022.06.001_bib130","doi-asserted-by":"crossref","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","article-title":"An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)","volume":"270","author":"Lehmann","year":"1995","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.livres.2022.06.001_bib131","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature05894","article-title":"Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance","volume":"447","author":"Odegaard","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.livres.2022.06.001_bib132","doi-asserted-by":"crossref","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.livres.2022.06.001_bib133","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.livres.2022.06.001_bib134","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.livres.2022.06.001_bib135","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A\u00a0randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.livres.2022.06.001_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106170","article-title":"A\u00a0randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study","volume":"98","author":"Sven","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.livres.2022.06.001_bib137","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatol Commun"}],"container-title":["Liver Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568422000344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542568422000344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:46:35Z","timestamp":1762872395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542568422000344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2542568422000344"],"URL":"https:\/\/doi.org\/10.1016\/j.livres.2022.06.001","relation":{},"ISSN":["2542-5684"],"issn-type":[{"value":"2542-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Liver Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.livres.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Third Affiliated Hospital of Sun Yat-sen University. Publishing services by Elsevier B. V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}]}}